Cargando…

Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study

INTRODUCTION: Cost-containment strategies are shifting the treatment of acute bacterial skin and skin structure infections (ABSSSI) from inpatient to outpatient settings. Current standard of care (SoC) requires multiple-dose regimens, which are associated with high hospitalization rates and high cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Anastasio, Patrick J., Wolthoff, Pete, Galli, Annmarie, Fan, Weihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336420/
https://www.ncbi.nlm.nih.gov/pubmed/28078655
http://dx.doi.org/10.1007/s40121-016-0145-7
_version_ 1782512208051175424
author Anastasio, Patrick J.
Wolthoff, Pete
Galli, Annmarie
Fan, Weihong
author_facet Anastasio, Patrick J.
Wolthoff, Pete
Galli, Annmarie
Fan, Weihong
author_sort Anastasio, Patrick J.
collection PubMed
description INTRODUCTION: Cost-containment strategies are shifting the treatment of acute bacterial skin and skin structure infections (ABSSSI) from inpatient to outpatient settings. Current standard of care (SoC) requires multiple-dose regimens, which are associated with high hospitalization rates and high costs. Oritavancin, a new single-dose antibiotic for ABSSSI, may be suitable for outpatient therapy. This analysis evaluates the effectiveness, costs, and resource utilization of oritavancin vs. SoC in a real-world, outpatient setting. METHODS: A single-site, retrospective chart review was conducted of 118 adult patients diagnosed with ABSSSI and treated with either single-dose oritavancin or multi-dose SoC therapy between 6 August 2014 and 30 June 2015. Patients were assigned to two matched cohorts: oritavancin and SoC. Primary clinical effectiveness endpoints was the success (cured or improved) at 5–30 days after the course of antibiotic therapy has been completed. Secondary economic endpoints were total costs and healthcare resource utilization. RESULTS: Oritavancin showed comparable clinical effectiveness vs. multi-dose SoC in the outpatient setting. A similar percentage of patients in the oritavancin (90.2%) and SoC cohorts (77.4%) achieved successful outcomes (“cure” or “improved”), with the cure rate higher for oritavancin (73.2%) vs. SoC (48.4%; P = 0.0315). Oritavancin’s clinical effectiveness was consistent across patient subgroups with varying demographic, clinical, and ABSSSI characteristics. Oritavancin was consistently associated with lower costs (per-patient savings $2319) and reduced resource utilization measures, and it required just 1.0 day of therapy vs. 7.2 days for SoC. CONCLUSION: Oritavancin is well suited for the outpatient treatment of ABSSSI. Compared with SoC, oritavancin offers comparable effectiveness, is more economical, and requires fewer healthcare resources.
format Online
Article
Text
id pubmed-5336420
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-53364202017-03-16 Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study Anastasio, Patrick J. Wolthoff, Pete Galli, Annmarie Fan, Weihong Infect Dis Ther Original Research INTRODUCTION: Cost-containment strategies are shifting the treatment of acute bacterial skin and skin structure infections (ABSSSI) from inpatient to outpatient settings. Current standard of care (SoC) requires multiple-dose regimens, which are associated with high hospitalization rates and high costs. Oritavancin, a new single-dose antibiotic for ABSSSI, may be suitable for outpatient therapy. This analysis evaluates the effectiveness, costs, and resource utilization of oritavancin vs. SoC in a real-world, outpatient setting. METHODS: A single-site, retrospective chart review was conducted of 118 adult patients diagnosed with ABSSSI and treated with either single-dose oritavancin or multi-dose SoC therapy between 6 August 2014 and 30 June 2015. Patients were assigned to two matched cohorts: oritavancin and SoC. Primary clinical effectiveness endpoints was the success (cured or improved) at 5–30 days after the course of antibiotic therapy has been completed. Secondary economic endpoints were total costs and healthcare resource utilization. RESULTS: Oritavancin showed comparable clinical effectiveness vs. multi-dose SoC in the outpatient setting. A similar percentage of patients in the oritavancin (90.2%) and SoC cohorts (77.4%) achieved successful outcomes (“cure” or “improved”), with the cure rate higher for oritavancin (73.2%) vs. SoC (48.4%; P = 0.0315). Oritavancin’s clinical effectiveness was consistent across patient subgroups with varying demographic, clinical, and ABSSSI characteristics. Oritavancin was consistently associated with lower costs (per-patient savings $2319) and reduced resource utilization measures, and it required just 1.0 day of therapy vs. 7.2 days for SoC. CONCLUSION: Oritavancin is well suited for the outpatient treatment of ABSSSI. Compared with SoC, oritavancin offers comparable effectiveness, is more economical, and requires fewer healthcare resources. Springer Healthcare 2017-01-11 2017-03 /pmc/articles/PMC5336420/ /pubmed/28078655 http://dx.doi.org/10.1007/s40121-016-0145-7 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Anastasio, Patrick J.
Wolthoff, Pete
Galli, Annmarie
Fan, Weihong
Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study
title Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study
title_full Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study
title_fullStr Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study
title_full_unstemmed Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study
title_short Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study
title_sort single-dose oritavancin compared to standard of care iv antibiotics for acute bacterial skin and skin structure infection in the outpatient setting: a retrospective real-world study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336420/
https://www.ncbi.nlm.nih.gov/pubmed/28078655
http://dx.doi.org/10.1007/s40121-016-0145-7
work_keys_str_mv AT anastasiopatrickj singledoseoritavancincomparedtostandardofcareivantibioticsforacutebacterialskinandskinstructureinfectionintheoutpatientsettingaretrospectiverealworldstudy
AT wolthoffpete singledoseoritavancincomparedtostandardofcareivantibioticsforacutebacterialskinandskinstructureinfectionintheoutpatientsettingaretrospectiverealworldstudy
AT galliannmarie singledoseoritavancincomparedtostandardofcareivantibioticsforacutebacterialskinandskinstructureinfectionintheoutpatientsettingaretrospectiverealworldstudy
AT fanweihong singledoseoritavancincomparedtostandardofcareivantibioticsforacutebacterialskinandskinstructureinfectionintheoutpatientsettingaretrospectiverealworldstudy